Pharvaris is a clinical-stage company focused on the discovery and development of oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications. The company provides alternatives to injected therapies for all sub-types of HAE and other related diseases.